Literature DB >> 12197869

Bacillus anthracis and antibacterial agents.

A Bryskier1.   

Abstract

Anthrax is one of the oldest threats to humankind, and remains endemic in animals in many parts of the world. Human cases are infrequent, and some result from biological warfare. This review summarizes the current knowledge on the antibacterial activity of available antibiotics. For potential use in the most severe cases of anthrax, antibacterials need to exhibit potent in vitro activity, intracellular bioactivity, and suitable locations in lymph nodes. In animal models, it has been shown that doxycycline and fluoroquinolones are the most active compounds. There is a lack of data for animal models for macrolides and ketolides, some of them exhibiting good in vitro activity. However, systemic anthrax (inhalation or gastrointestinal) is mainly due to anthrax toxin, and therapy directed against intoxication is needed as basic treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12197869     DOI: 10.1046/j.1469-0691.2002.00527.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  11 in total

1.  Structure determination and interception of biosynthetic intermediates for the plantazolicin class of highly discriminating antibiotics.

Authors:  Katie J Molohon; Joel O Melby; Jaeheon Lee; Bradley S Evans; Kyle L Dunbar; Stefanie B Bumpus; Neil L Kelleher; Douglas A Mitchell
Journal:  ACS Chem Biol       Date:  2011-10-06       Impact factor: 5.100

Review 2.  Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins.

Authors:  Holger Barth; Klaus Aktories; Michel R Popoff; Bradley G Stiles
Journal:  Microbiol Mol Biol Rev       Date:  2004-09       Impact factor: 11.056

3.  PlyPH, a bacteriolytic enzyme with a broad pH range of activity and lytic action against Bacillus anthracis.

Authors:  Pauline Yoong; Raymond Schuch; Daniel Nelson; Vincent A Fischetti
Journal:  J Bacteriol       Date:  2006-04       Impact factor: 3.490

4.  Novel and unique diagnostic biomarkers for Bacillus anthracis infection.

Authors:  Sagit Sela-Abramovich; Theodor Chitlaru; Orit Gat; Haim Grosfeld; Ofer Cohen; Avigdor Shafferman
Journal:  Appl Environ Microbiol       Date:  2009-07-31       Impact factor: 4.792

5.  Delineation of the Residues of Bacillus anthracis Zinc Uptake Regulator Protein Directly Involved in Its Interaction with Cognate DNA.

Authors:  Divya Kandari; Hemant Joshi; Neetu Tanwar; Manoj Munde; Rakesh Bhatnagar
Journal:  Biol Trace Elem Res       Date:  2020-10-14       Impact factor: 3.738

6.  In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin.

Authors:  Lance B Price; Amy Vogler; Talima Pearson; Joseph D Busch; James M Schupp; Paul Keim
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

7.  Activation of inhibitors by sortase triggers irreversible modification of the active site.

Authors:  Anthony W Maresso; Ruiying Wu; Justin W Kern; Rongguang Zhang; Dorota Janik; Dominique M Missiakas; Mark-Eugene Duban; Andrzej Joachimiak; Olaf Schneewind
Journal:  J Biol Chem       Date:  2007-06-01       Impact factor: 5.157

8.  Treatment and prophylaxis of anthrax by new neurosecretory cytokines.

Authors:  A A Galoyan; S L Grigoryan; K V Badalyan
Journal:  Neurochem Res       Date:  2006-06-28       Impact factor: 4.414

9.  Passive protection against anthrax in mice with plasma derived from horses hyper-immunized against Bacillus anthracis Sterne strain.

Authors:  Marc Caldwell; Terri Hathcock; Kenny V Brock
Journal:  PeerJ       Date:  2017-12-15       Impact factor: 2.984

10.  Loss of Bacitracin Resistance Due to a Large Genomic Deletion among Bacillus anthracis Strains.

Authors:  Yoshikazu Furuta; Hayato Harima; Emiko Ito; Fumito Maruyama; Naomi Ohnishi; Ken Osaki; Hirohito Ogawa; David Squarre; Bernard Mudenda Hang'ombe; Hideaki Higashi
Journal:  mSystems       Date:  2018-10-30       Impact factor: 6.496

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.